Rubella, also known as German measles or three-day measles, is a vaccine-preventable infection caused by the rubella virus. A rash may start around two weeks after exposure and last for three days. People are infectious during the week before and after the appearance of the rash.

Rubella is a common infection in many areas of the world. Rates of disease have decreased in many areas as a result of vaccination. The name "rubella" is from Latin and means little red.

Signs and symptoms

thumb|upright=1.3|Young boy displaying the characteristic maculopapular rash of rubella

thumb|upright=1.3|Generalized rash on the abdomen due to rubella

Rubella has symptoms similar to those of the flu. However, the primary symptom of rubella virus infection is a rash (exanthem) on the face, which spreads to the trunk and limbs and usually fades after three days, which is why it is often referred to as three-day measles. The facial rash usually clears as it spreads to other parts of the body. Other symptoms include low-grade fever, swollen glands (sub-occipital and posterior cervical lymphadenopathy), joint pains, headache, and conjunctivitis.

The swollen glands or lymph nodes can persist for up to a week, and the fever rarely rises above 38 °C (100.4 °F). The rash of rubella is typically pink or light red. The rash causes itching and often lasts for about three days. The rash disappears after a few days with no skin staining or peeling. When the rash clears up, the skin might shed in very small flakes where the rash covered it. Forchheimer spots occur in 20% of cases and are characterized by small, red papules on the area of the soft palate.

Rubella can affect anyone of any age. Adult females are particularly prone to arthritis and joint pains.

In children, rubella normally causes symptoms that last two days and include:

  • Rash begins on the face and spreads to the rest of the body.
  • Low fever of less than .
  • Posterior cervical lymphadenopathy.

In older children and adults, additional symptoms may be present, including

  • Swollen glands
  • Coryza (cold-like symptoms)
  • Aching joints (especially in young females)

Severe complications of rubella include:

  • Brain inflammation (encephalitis)

Coryza in rubella may convert to pneumonia, either direct viral pneumonia or secondary bacterial pneumonia, and bronchitis (either viral bronchitis or secondary bacterial bronchitis).

Congenital rubella syndrome

thumb|upright=1.3|Child with cataracts in both eyes due to congenital rubella syndrome

Rubella can cause congenital rubella syndrome in the newborn; it is the most severe sequela of rubella. The syndrome (CRS) follows intrauterine infection by the rubella virus and comprises cardiac, cerebral, ophthalmic, and auditory defects. It may also cause prematurity, low birth weight, neonatal thrombocytopenia, anemia, and hepatitis. Neurodevelopmental disorders, including autism, are common.

The risk of major defects in organogenesis is highest for infection in the first trimester. CRS is the main reason a rubella vaccine was developed. 80–90% of mothers who contract rubella within the critical first trimester have either a miscarriage or a stillborn baby.

About 100,000 cases of this condition occur each year. that is enveloped and has a single-stranded RNA genome. Contact with respiratory droplets containing rubella virus transmits the virus. It then replicates in the nasopharynx and lymph nodes. The virus is found in the blood 5 to 7 days after infection and spreads throughout the body. The virus has teratogenic properties. It can cross the placenta and infect the fetus, where it interrupts cellular development or destroys cells.

Diagnosis

Rubella virus-specific IgM antibodies are present in people recently infected with the rubella virus. These antibodies can persist for over a year, and a positive test result needs to be interpreted with caution. The presence of these antibodies, along with or a short time after the characteristic rash, confirms the diagnosis.

Prevention

Rubella infections are prevented by active immunization programs using live attenuated virus vaccines. Two live attenuated virus vaccines, RA 27/3 and Cendehill strains, were effective in preventing adult disease. However, their use in prepubertal females did not produce a significant fall in the overall incidence rate of CRS in the UK. Reductions were achieved through immunisation of all children.

The vaccine is now usually given as part of the MMR vaccine. The WHO recommends the first dose be given at 12 to 18 months of age with a second dose at 36 months. Pregnant women are usually tested for immunity to rubella early on. Women found to be susceptible are not vaccinated until after the baby is born because the vaccine contains a live virus.

The immunisation program has been quite successful. Cuba declared the disease eliminated in the 1990s, and in 2004 the Centers for Disease Control and Prevention announced that both the congenital and acquired forms of rubella had been eliminated from the United States. The World Health Organization declared Australia rubella-free in October 2018.

Screening for rubella susceptibility by history of vaccination or by serology is recommended in the United States for all women of childbearing age at their first preconception counseling visit to reduce incidence of congenital rubella syndrome (CRS). It is recommended that all susceptible non-pregnant women of childbearing age should be offered rubella vaccination.

Treatment

There is no specific treatment for rubella; however, the cornerstone of management is supportive care to diminish discomfort. Treatment of newborns focuses on managing complications. Congenital heart defects and cataracts can be corrected by direct surgery.

Management for ocular congenital rubella syndrome (CRS) is similar to that for age-related macular degeneration, including counseling, regular monitoring, and the provision of low vision devices, if required.

Prognosis

Rubella infection in children and adults is usually mild, self-limiting, and often asymptomatic. The prognosis in children born with CRS is poor.

Epidemiology

Rubella occurs worldwide. The virus tends to peak during the spring in countries with temperate climates. Before the vaccine against rubella was introduced in 1969, widespread outbreaks usually occurred every 6–9 years in the United States and 3–5 years in Europe, mostly affecting children in the 5-9-year-old age group. Since the introduction of vaccine, occurrences have become rare in those countries with high uptake rates.

Vaccination has interrupted the transmission of rubella in the Americas: no endemic case has been observed since February 2009. Vaccination is still strongly recommended as the virus could be reintroduced from other continents should vaccination rates in the Americas drop. During the epidemic in the US between 1962 and 1965, rubella virus infections during pregnancy were estimated to have caused 30,000 stillbirths and 20,000 children to be born impaired or disabled as a result of CRS. Universal immunisation producing a high level of herd immunity is important in the control of epidemics of rubella.

In the UK, a large population of unvaccinated men remains susceptible to rubella. Outbreaks of rubella occurred amongst many young men in the UK in 1993, and in 1996, the infection was transmitted to pregnant women, many of whom were immigrants and were susceptible. Outbreaks still arise, usually in developing countries where the vaccine is not as accessible. The complications encountered in pregnancy from rubella infection (miscarriage, fetal death, congenital rubella syndrome) are more common in Africa and Southeast Asia at a rate of 121 per 100,000 live births compared to 2 per 100,000 live births in the Americas and Europe.

In Japan, 15,000 cases of rubella and 43 cases of congenital rubella syndrome were reported to the National Epidemiological Surveillance of Infectious Diseases between October 15, 2012, and March 2, 2014, during the 2012–13 rubella outbreak in Japan. They mainly occurred in men aged 31–51 and young adults aged 24–34.

History

Rubella was first described in the mid-eighteenth century. German physician and chemist, Friedrich Hoffmann, made the first clinical description of rubella in 1740, which was confirmed by De Bergen in 1752 and Orlow in 1758.

In 1814, George de Maton first suggested that it be considered a disease distinct from both measles and scarlet fever. All these physicians were German, and the disease was known as Rötheln (contemporary German Röteln). (Rötlich means "reddish" or "pink" in German.) The fact that three Germans described it led to the common name of "German measles." Henry Veale, an English Royal Artillery surgeon, described an outbreak in India. He coined the name "rubella" (from the Latin word, meaning "little red") in 1866.

It was formally recognised as an individual entity in 1881, at the International Congress of Medicine in London. In 1914, Alfred Fabian Hess theorised that rubella was caused by a virus, based on work with monkeys. In 1938, Hiro and Tosaka confirmed this by passing the disease to children using filtered nasal washings from acute cases. The virus was isolated in tissue culture in 1962 by two separate groups led by physicians Paul Douglas Parkman and Thomas Huckle Weller.

In 1967, the molecular structure of rubella was observed under electron microscopy using antigen-antibody complexes by Jennifer M. Best, June Almeida, J E Banatvala and A P Waterson.

In 1969, a live attenuated virus vaccine was licensed. On April 29, 2015, the Americas became the first WHO region to officially eradicate the disease. The last non-imported cases occurred in 2009 in Argentina and Brazil. The Pan American Health Organization director remarked, "The fight against rubella has taken more than 15 years, but it has paid off with what I believe will be one of the most important pan-American public health achievements of the 21st Century." The declaration was made after 165 million health records and genetically confirming that imported strains of the virus caused all recent cases. Rubella is still common in some regions of the world and Susan E. Reef, team lead for rubella at the CDC's global immunization division, who joined in the announcement, said there was no chance it would be eradicated worldwide before 2020.

The name rubella is sometimes confused with rubeola, an alternative name for measles in English-speaking countries; the diseases are unrelated. In some other European languages, like Spanish, rubella and rubeola are synonyms, and rubeola is not an alternative name for measles. Thus, in Spanish, rubeola refers to rubella and sarampión refers to measles.

See also

  • Blueberry muffin baby
  • Eradication of infectious diseases
  • Exanthema subitum (roseola infantum)

References

  • Rubella at Wong's Virology.
  • Immunization Action Coalition: Rubella